989 East Hillsdale Blvd.
26 articles with Apollomics, Inc.
5/3/2019Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.
Apollomics, Inc. announced that Fabio M. Benedetti, M.D. has joined the senior leadership team as Chief Medical Officer (CMO).
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
Activity Demonstrated as a Single Agent and in Combination with an anti-PD-1 antibody
Wilson W. Cheung, CPA appointed Chief Financial Officer
Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs
CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors
Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT's clinical development program for CBT-101.
CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments
CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor
CBT Pharmaceuticals Awarded NIH Small Business Innovation Research Grant Towards Development of Combination Checkpoint Inhibition
CBT Pharmaceuticals today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services National Cancer Institute (NCI) of the National Institutes of Health (NIH).
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
CBT Pharmaceuticals Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the receipt of ethics approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its planned APOLLO-1 clinical trial.
CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors
CBT Pharmaceuticals today announced the continuation of the CBT-501 Phase 1 clinical trial with the initiation of the Phase 1b segment of the study in patients with select advanced or relapsed/recurrent solid tumors.
CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy
CBT Pharmaceuticals (CBT) and CrystalGenomics, Inc., (KOSDAQ:083790) today announced a co-development agreement for an investigational combination therapy of CBT-501 and CG200745 across a variety of solid tumors with high unmet medical needs.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, presented preclinical in-vivo data and animal safety pharmacology studies of CBT-102
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
Crown Bioscience and a global drug discovery and development services company announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company.
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics
CBT Pharma presented preclinical data which showed that CBT-502 efficiently inhibited binding of PD-L1 with no binding to PD-L2, CD28, ICOS or CTLA4.
CBT Pharma Announces First U.S. Patient Dosed In Phase 1 Clinical Trial Of C-Met Inhibitor, CBT-101, For Advanced Solid Tumors With C-Met Dysregulation
CBT Pharma today announced that the first subject has been dosed in the Phase I multi-center study, CBT-101-01 which is an important milestone for CBT and its employees.